

NATIONAL INSTITUTE FOR HEALTH CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Erlotinib for the treatment of EGFR mutation positive non-small-cell lung cancer

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:				
Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	Proposal:	Proposal made by:	Action taken: Removed/Added/Not included/Noted	Justification:
1.	The matrix should be amended so the Welsh Assembly Government becomes Welsh Government	NICE Secretariat	Added	The Welsh Government removed 'Assembly' from its title in May 2011. The Matrix has been amended to recognise this change.
2.	The matrix should be amended so NHS QIS becomes Healthcare Scotland	NICE Secretariat	Added	NHS Quality Improvement Scotland has changed its name to Healthcare Improvement Scotland. The Matrix has been altered to reflect this under consultees and commentators under 'general'.

Appendix D

3.	Changes in comparator manufacturers	NICE Secretariat	Added	The list of comparator manufacturers has been amended following the scoping workshop to reflect current practice.
4.	Change Public Health Groups from tbc to none	NICE Secretariat	Added	No Public Health groups were identified during the matrix consultation.
5.	Remove British Oncological Association	NICE Secretariat	Removed	This organisation has ceased operations.
6.	Remove Policy Research Institute on Ageing and Ethnicity	NICE Secretariat	Removed	This organisation has requested to be removed from all appraisals.